{"entity":{"id":"nct05254743","kind":"trial","name":"A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","aka":["BRUIN-CLL-314"],"tldr":"A phase 3 trial of Pirtobrutinib and Ibrutinib in chronic lymphocytic leukaemia, run by Loxo Oncology, Inc., now recruiting.","summary":"A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) is a phase 3 interventional study registered as NCT05254743 by Loxo Oncology, Inc., with 737 participants planned, started 2022-07-22 and due to reach its primary completion in 2027-10. Interventions recorded: Pirtobrutinib and Ibrutinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05254743","url":"https://clinicaltrials.gov/study/NCT05254743"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["pirtobrutinib","ibrutinib"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05254743","phase":"3","setting":"A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)","sponsor":"Loxo Oncology, Inc.","participation":[{"nct":"NCT05254743","source":"https://clinicaltrials.gov/study/NCT05254743","fetchedAt":"2026-10-07T16:53:38.157Z","studySha256":"2e69c33750377c558ac73f7cf005b7c7c68a383348a34c8ca0549d4eae51984b","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-17","leadSponsor":"Loxo Oncology, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":737,"enrolmentType":"ESTIMATED","siteCount":143,"recruitingSiteCount":93,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","France","Germany","Hungary","Israel","Italy","Japan","New Zealand","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2022-07-22","startedType":"actual","enrolled":737,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05254743/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"},{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}